The Siegfried Group has in the meantime overcome the effects of the cyber attack that occurred before Pentecost. While the two sites in Barcelona were not affected and continued production uninterrupted, other sites also managed to maintain operations to varying degrees or to resume them after a short break. As of this week, full production can be resumed throughout the Siegfried network. The only exception is the smallest site in terms of sales in Hal Far (Malta), for which production is expected to resume within the next few days.
The forensic investigations, which have been completed in the meantime, have confirmed that no sensitive customer data was compromised. There has been no permanent damage to Siegfried's IT infrastructure, IT systems or equipment.
As previously communicated, the business interruption has resulted in volume and revenue shortfalls with cost continuing to run, which will have an impact on the half-year results. As the interruption has been kept short, the Siegfried Group continues to expect to be able to meet its targets for the full year, with demand for its services and products remaining high.
The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2020, the Siegfried group achieved sales of CHF 845.1 million and currently employs approximately 3'500 people at eleven sites on three continents. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.